Transdermal Drug Delivery Systems Market | Industry Insight 2019-2026 Covered Players – Hisamitsu Pharmaceutical, Mylan, UCB, Novartis, GlaxoSmithKline, Johnson & Johnson

img

Market Size – USD 5.65 Billion in 2018, Market Growth – CAGR of 4.5%, Market Trends – Product launches and research for advanced transdermal drug delivery system

According to the current analysis of Reports and Data, the Transdermal Drug Delivery Systems market was valued at USD 5.65 Billion in 2018 and is anticipated to reach USD 8.03 Billion by the year 2026, at a CAGR of 4.5%. These systems are an excellent alternative to the oral, intravascular, subcutaneous, and transmucosal routes, where medications are administered through the skin for therapeutic purposes. This industry has witnessed the development of new adhesives, molecular absorption enhancers, and penetration enhancers that are expected to improve skin permeability, which will expand the range of transdermally administrable drugs. New technology, such as the improved micro-needle supply, makes it easy to carry the drug through the skin without feeling pain.

Here, you can avail sample PDF pages and 30 mins free consultation: https://www.reportsanddata.com/sample-enquiry-form/2272

The market is divided into five categories according to the applications, namely pain management, central nervous system disorders, hormonal applications, cardiovascular diseases and other applications such as smoking cessation, vertigo and the treatment of overactive bladder. By 2018, the pain management segment is expected to represent the majority of the market for transdermal drug delivery systems. Most of this segment can be attributed to the increasing availability of transdermal products for the treatment of pain. On technology basis, the market is classified in the fields of thermal, iontophoresis, electroporation, ultrasound, electrical current, microporation, mechanical matrices, and radio frequencies. Depending on the type of distribution system, it is classified in the passive and active distribution systems. Passive administration systems are further classified as a matrix system and a repository system. Dynamic distribution systems are classified into structure, electricity, and others.

These drug delivery products are medicated adhesive patch that can be applied on the skin to give a specific dose of medication through the skin and into the blood. This often helps to heal a part of the injured body. An advantage of the transdermal drug delivery route is that the patch provides the patient with controlled release of the medicine, typically through a porous membrane overlying a reservoir of medication or body heat that melt thin adhesive medicine layers It is best to administer other types of medications, such as oral, topical, intravenous, intramuscular, etc. It is anticipated that the increase in the geriatric population and the number of patients with chronic conditions will stimulate the growth of this industry. In addition, the growing adoption of third-generation transdermal drug delivery systems, such as iontophoresis, is increasing market growth. It is largely due to the overall increase in the prevalence of chronic diseases. In addition, technological advances in drug delivery systems are expected to support the progress of target product in the coming years. However, the disadvantages of these delivery systems, such as application site irritation and edema, should hinder market growth. Medication failures and withdrawals from transdermal drug delivery systems are also expected to limit market growth to some extent.

Further key findings from the report suggest

  • Transdermal Drug Delivery System market is growing at a CAGR of 5.5% in Asia-Pacific, followed by North America and Europe, with 4.3 % and 4.2% CAGR, respectively. High prevalence of chronic diseases across the globe is the key factor in accelerating market growth during the forecast period across all regions.
  • As of 2018, Patches is dominating the target market which holds 43.9% of the global market. North America regional market is the chief revenue generating source for this product segment, followed by Asia-Pacific and European regions.
  • Little technological advance in the transdermal drug delivery market is related to the modification of transdermal patch design, incorporation of pressure-sensitive adhesives, and permeation enhancers.
  • The foregoing results in improved drug delivery and higher drug retention capacity in larger amounts is expected to stimulate market demand for the target market during the forecast period.
  • Transdermal patches provide better control over toxicity levels because they can be easily removed if the drug is tested for more significant toxic effects.
  • Technological inventions such as the inclusion of micro-needles assemblies in patches improve the accuracy of medication delivery.
  • Since the first transdermal patch was approved in 1981 to prevent nausea and vomiting associated with motion sickness, the FDA has supported more than 35 transdermal patches covering 13 molecules over the past 22 years.
  • Key participants Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), and GlaxoSmithKline (UK). Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).

Have a Question for us or Specific Requirements? Ask our Industry Expert @ https://www.reportsanddata.com/make-enquiry-form/2272

For the purpose of this report, Reports and Data has segmented the Transdermal Drug Delivery System market on the basis of type, technology type, applications type, end use, and region:

Type (Revenue, USD Million; 2016–2026)

  • Patches
  • Semisolid formulations
  • Others

Technology Type (Revenue, USD Million; 2016–2026)

  • Thermal
  • Iontophoresis
  • Electroporation
  • Ultrasound
  • Electric Current
  • Microporation
  • Mechanical Arrays
  • Radio Frequency

Applications Type (Revenue, USD Million; 2016–2026)

  • Pain Management,
  • Central Nervous System Disorders,
  • Hormonal Applications,
  • Cardiovascular Diseases

End Use (Revenue, USD Million; 2016–2026)

  • Hospital
  • Clinic
  • Others

Regional Outlook (Revenue in USD Million; 2016–2026)

  • North America (U.S., Canada)
  • Europe (Germany, France, UK, Spain, Italy, Rest of the Europe)
  • Asia Pacific (China, India, Japan, Rest of Asia-Pacific)
  • Middle East & Africa
  • Latin America (Brazil)

For Further Details about this Market Visit: https://www.reportsanddata.com/report-detail/transdermal-drug-delivery-systems-market

About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Email

Go to website